Business context and reporting period
This is ChromaDex Corporation’s unaudited Form 10-Q for the quarter ended September 27, 2014, with comparisons to the quarter ended September 28, 2013 and the corresponding nine-month periods. The filing describes a natural-products business spanning reference standards and contract services, proprietary ingredients, and scientific and regulatory consulting. The request identifies Niagen Bioscience, Inc., but the filing itself names ChromaDex Corporation.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Net sales | $4.14 million | $2.72 million | $11.07 million | $7.76 million |
| Gross profit | $1.52 million | $0.75 million | $3.91 million | $2.38 million |
| Gross margin | 36.8% | 27.6% | 35.3% | 30.7% |
| Operating loss | $0.65 million | $1.24 million | $4.13 million | $3.67 million |
| Net loss | $0.66 million | $1.25 million | $4.16 million | $3.70 million |
| Loss per share | $0.01 | $0.01 | $0.04 | $0.04 |
- Q3 sales increased 52%; nine-month sales increased 43%. Ingredients revenue grew 160% in Q3 and 141% for nine months, including sales of NIAGEN, PTEROPURE and PURENERGY. Core standards and contract services also grew; consulting revenue declined.
- Gross margin improved, which management attributed to product mix, higher sales and utilization, and ingredient purchasing efficiencies. Nine-month general and administrative expense rose to $6.46 million from $4.16 million, including higher share-based compensation, increased R&D and personnel costs, and a $125,000 legal settlement.
- At September 27, 2014, cash was $1.20 million, current assets were $6.31 million and current liabilities were $3.58 million; the current ratio was approximately 1.76. Total assets were $8.70 million and stockholders’ equity was $4.50 million.
- Capital lease obligations totaled approximately $620,000, including current maturities. Nine-month operating cash outflow was $2.33 million; investing activities provided $0.95 million and financing activities provided $0.33 million. Cash declined by $1.06 million from year-end 2013.
Material changes, outlook and risks
- Nine-month net loss increased about 13% year over year despite higher revenue and gross profit. Operating cash use also increased modestly. Receivables rose substantially, contributing to cash consumption.
- After quarter-end, the company entered a secured loan agreement providing up to $5 million: $2.5 million was funded at closing, with another $2.5 million available at the company’s option through July 31, 2015. The loan carries interest of at least 9.35%, includes a 12-month interest-only period and 30-month repayment schedule, and is secured by substantially all assets other than specified exclusions. It also includes a warrant for 419,020 shares and potential principal conversion into up to $1 million of stock.
- Management said cash and expected operating cash flows, together with the loan, were expected to support projected operations through at least November 6, 2015. Management cautioned that additional financing might be needed and might not be available on favorable terms or at all; inability to obtain funding could constrain expansion and adversely affect the business. This is an expectation, not a guarantee.
- No numerical sales or earnings guidance was provided. Management planned to increase R&D for proprietary ingredients over the next two years, subject to available resources.
- Risks highlighted include customer demand and market acceptance, competition, intellectual-property protection and litigation, regulation of supplements and ingredients, manufacturing capacity, and financing needs. A September 2014 UC license amendment added exclusive rights for specified uses of Pterostilbene, with fees, royalties and milestone payments.
- The filing reports no legal proceedings believed likely to have a material adverse effect; it does disclose a $125,000 settlement paid during the nine-month period. The company also reported effective disclosure controls and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for ChromaDex Corporation, not an entity named Niagen Bioscience, Inc.
- Track whether ingredient sales growth—particularly NIAGEN—continues, and whether it converts into sustainable gross profit and operating cash flow.
- Review receivables, collections, inventory valuation and cash burn, as liquidity remained limited at quarter-end.
- Verify the loan’s final terms and funding, any draw on the remaining commitment, covenant compliance, collateral and potential dilution from conversion rights and the warrant.
- Assess the sustainability of elevated share-based compensation and the costs and commercial milestones associated with the amended UC license.